Show simple item record

dc.contributor.authorRufino, Jesús
dc.contributor.authorBaquero, Carlos
dc.contributor.authorFrey, Davide
dc.contributor.authorGlorioso, Christin
dc.contributor.authorOrtega, Antonio
dc.contributor.authorReščič, Nina
dc.contributor.authorRoberts, Julian C
dc.contributor.authorLillo, Rosa Elvira
dc.contributor.authorMenezes, Raquel
dc.contributor.authorChampati, Jaya Prakash 
dc.contributor.authorFernández Anta, Antonio 
dc.date.accessioned2022-07-11T12:37:05Z
dc.date.available2022-07-11T12:37:05Z
dc.date.issued2022-08-15
dc.identifier.urihttp://hdl.handle.net/20.500.12761/1603
dc.description.abstractData collected in the Global COVID-19 Trends and Impact Surveys (UMD Global CTIS), and data on variants sequencing from GISAID, are used to evaluate the impact of the Omicron variant (in South Africa and other countries) on the prevalence of COVID-19 among unvaccinated and vaccinated population, in general and discrim- inating by the number of doses. In South Africa, we observe that the prevalence of COVID-19 in December (with strong presence of Omicron) among the unvaccinated population is comparable to the prevalence during the previous wave (in August-September), in which Delta was the variant with the largest presence. However, among vaccinated, the prevalence of COVID-19 in December is much higher than in the previous wave. In fact, a significant re- duction of the vaccine efficacy is observed from August-September to December. For instance, the efficacy drops from 0.81 to 0.30 for those vaccinated with 2 doses, and from 0.51 to 0.09 for those vacci- nated with one dose. The study is then extended to other countries in which Omicron has been detected, comparing the situation in October (before Omicron) with that of December. While the re- duction measured is smaller than in South Africa, we still found, for instance, an average drop in vaccine efficacy from 0.53 to 0.45 among those vaccinated with two doses. Moreover, we found a significant negative (Pearson) correlation of around −0.6 between the measured prevalence of Omicron and the vaccine efficacy.es
dc.language.isoenges
dc.titleUsing Survey Data to Estimate the Impact of the Omicron Variant on Vaccine Efficacy against COVID-19 Infectiones
dc.typeconference objectes
dc.conference.date15 August 2022es
dc.conference.placeWashington DC, USAes
dc.conference.titleepiDAMIK 5.0: The 5th International workshop on Epidemiology meets Data Mining and Knowledge discovery*
dc.event.typeworkshopes
dc.pres.typepaperes
dc.rights.accessRightsopen accesses
dc.relation.projectNameCOMODIN-CM (COVID-19 Monitoring via Data-Intensive Analysis)es
dc.description.refereedTRUEes
dc.description.statuspubes


Files in this item

This item appears in the following Collection(s)

Show simple item record